Company Description
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein.
The company’s NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration.
It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
The company’s platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications.
Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
| Country | United States |
| Founded | 2004 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Jeffrey Frelick |
Contact Details
Address: 2 Burlington Woods Drive, Suite 100 Burlington, Massachusetts 01803 United States | |
| Phone | 781 552 4452 |
| Website | bonebiologics.com |
Stock Details
| Ticker Symbol | BBLGW |
| Exchange | NASDAQ |
| Stock Type | Warrants |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001419554 |
| CUSIP Number | 098070113 |
| ISIN Number | US0980701546 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey Frelick | Chief Executive Officer and President |